Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes

Understanding Non-small Cell Lung Cancer (NSCLC) Patient Characteristics, Treatment Patterns and Outcomes Via Cross-sEctional Physicians suRvey-based Chart Audit

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07215026

Acronym

UNCOVER

Enrollment

833

Registered

2025-10-10

Start date

2025-10-27

Completion date

2026-01-21

Last updated

2026-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

Non-small cell lung cancer

Brief summary

Detailed description

This is a retrospective, cross-sectional, non-interventional, multi-country survey-based chart audit study to evaluate real-world treatment patterns, patient clinical profiles, and clinical outcomes among aNSCLC patients receiving at least 1L SACT in Argentina, Brazil, Mexico, Australia, India, Taiwan, Malaysia, Hong Kong, and Turkey. All patient-level data, including patient demographic and clinical characteristics, treatment history, and clinical outcomes, will be collected retrospectively from existing patient medical records provided by participating physicians, without interference with treatment decisions. Informed consent from individual patients will not be required, as this study describes the analysis of deidentified patient data.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Patient Eligibility Criteria - Inclusion Criteria Diagnosis: Confirmed de novo stage IIIB, IIIC, or IV NSCLC. Biomarker Status: Either: EGFR mutation present Or: No actionable gene alterations (AGAs) detected (including EGFR, ALK, ROS1, NTRK, BRAF V600E, RET, MET, KRAS, HER2; patients not tested for these also eligible). Treatment Start Window: Initiated 1L SACT (systemic anticancer therapy) for advanced NSCLC between the date of first Tagrisso® (osimertinib) approval for NSCLC in their country and 31 December 2024. Age: 18 years or older at time of 1L SACT initiation. \-

Exclusion criteria

Concurrent Malignancies: Patients on active treatment for another primary malignancy at 1L SACT initiation.

Design outcomes

Primary

Measure	Time frame	Description
Outcomes of interest are real-world overall survival (rwOS)	12 month	Definition of rwOS rwOS is defined as the interval between the index date and the date of death due to any cause. \*Patients who are alive or for whom vital status is unknown at the time of data collection will be censored at the date the patient is last known to be alive.

Countries

India

Outcome results